Mette Dahl

Dr. Mette Dahl


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2018 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
MDMette Dahl
Mette Dahl
IDIben Daugaard
Iben Daugaard
MAMaria Schertz Andersen
Maria Schertz Andersen
THThomas Birkballe Hansen
Thomas Birkballe Hansen
KGKirsten Grønbæk
Kirsten Grønbæk
LKLasse Kristensen
Lasse Kristensen
Circular RNAs (circRNAs) are covalently closed endogenous molecules with tissue- and disease-specific expression patterns, which have potential as diagnostic and prognostic biomarkers in cancer. The molecules are formed by a backsplicing event linking the 3′-end of an exon to the 5′-end of the same or an upstream exon, and they exert diverse regulatory functions important in carcinogenesis. The landscape of circRNA expression has not been characterized in B-cell malignancies, and current methods for circRNA quantification have several limitations that prevent development of clinically applicable assays. Here, we demonstrate that circRNAs can be accurately quantified without enzymatic reactions or bias using color-coded probes (NanoString technology). First, we performed high-throughput RNA sequencing (RNA-seq) of several mantle cell lymphoma and multiple myeloma cell lines to profile the genome-wide landscape of circRNA expression. We detected several circRNAs known to be deregulated in other cancers and identified a novel circRNA from the IKZF3 gene. Based on these data, we selected 52 unique circRNAs for which we designed color-coded probes spanning their specific backsplicing junctions. These circRNAs were quantified in cell lines and patient samples from several different B-cell malignancies (mantle cell lymphoma, multiple myeloma, follicular lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma and chronic lymphocytic leukemia) simultaneously using the NanoString technology. The circRNA expression profiles obtained could distinguish different B-cell malignancies, and confirmed the presence of the novel circRNA derived from IKZF3. The NanoString assays were specific for circRNA detection and data were more reproducible and quantitatively more accurate than RNA-seq data. In addition, we obtained high-quality data on severely degraded RNA samples from formalin-fixed, paraffin-embedded (FFPE) tissues. Together, we provide a map of circRNA expression in B-cell malignancies and present an enzyme-free digital counting methodology, which has the potential to become a new gold standard for circRNA quantification.

1 January 2011 in Human Reproduction Update
Verified
Journal Article
Open access
PDF file
MDMette Dahl
Mette Dahl
THThomas Vauvert F. Hviid
Thomas Vauvert F. Hviid
The human leucocyte antigen (HLA) class Ib molecules, HLA-E, -F and -G, are expressed at the materno-fetal interface. Because of the apparent immunoregulatory functions of these proteins, they may be involved in successful acceptance of the semi-allogenic fetus during pregnancy. The literature on polymorphisms of the three genes, expression patterns of the proteins, and interactions with immune cell receptors have been evaluated to elucidate whether HLA-E, -F and -G are involved in the pathogenesis of some cases of recurrent miscarriages and unexplained infertility. The HLA class Ib molecules seem to induce suppression of the maternal immune system, but are not necessarily fundamental factors for pregnancy success. However, evidence points towards low expression of these proteins, especially HLA-G, being associated with reduced fertility. To clarify the functions of HLA-E, -F and -G future studies need to link investigations of the polymorphisms in these genes to measurements of protein levels, and examine the role of these proteins in the complex interplay of immune cells and cytokines at the materno-fetal interface.

1 July 2012 in Human Immunology
Verified
Journal Article
Closed access
Ole Bjarne ChristiansenOle Bjarne Christiansen
Ole Bjarne Christiansen
AKAstrid M. Kolte
Astrid M. Kolte
MDMette Dahl
Mette Dahl
ELElisabeth C. Larsen
Elisabeth C. Larsen
RSRudi Steffensen
Rudi Steffensen
THThomas V. Hviid
Thomas V. Hviid

Verified
Journal Article
Open access
PDF file
MDMette Dahl
Mette Dahl
LKLasse Kristensen
Lasse Kristensen
KGKirsten Grønbæk
Kirsten Grønbæk
With the introduction of next generation sequencing methods, such as RNA sequencing, it has become apparent that alterations in the non-coding regions of our genome are important in the development of cancer. Particularly interesting is the class of long non-coding RNAs (lncRNAs), including the recently described subclass of circular RNAs (circRNAs), which display tissue- and cell-type specific expression patterns and exert diverse regulatory functions in the cells. B-cells undergo complex and tightly regulated processes in order to develop from antigen naïve cells residing in the bone marrow to the highly diverse and competent effector cells circulating in peripheral blood. These processes include V(D)J recombination, rapid proliferation, somatic hypermutation and clonal selection, posing a risk of malignant transformation at each step. The aim of this review is to provide insight into how lncRNAs including circRNAs, participate in normal B-cell differentiation, and how deregulation of these molecules is involved in the development of B-cell malignancies. We describe the prognostic value and functional significance of specific deregulated lncRNAs in diseases such as acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, Burkitt lymphoma and multiple myeloma, and we provide an overview of the current knowledge on the role of circRNAs in these diseases.

1 January 2014 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
MDMette Dahl
Mette Dahl
SDSnezana Djurisic
Snezana Djurisic
THThomas Vauvert Faurschou Hviid
Thomas Vauvert Faurschou Hviid
Pregnancy is an immunological paradox, where fetal antigens encoded by polymorphic genes inherited from the father do not provoke a maternal immune response. The fetus is not rejected as it would be theorized according to principles of tissue transplantation. A major contribution to fetal tolerance is the human leukocyte antigen (HLA)-G, a nonclassical HLA protein displaying limited polymorphism, restricted tissue distribution, and a unique alternative splice pattern. HLA-G is primarily expressed in placenta and plays multifaceted roles during pregnancy, both as a soluble and a membrane-bound molecule. Its immunomodulatory functions involve interactions with different immune cells and possibly regulation of cell migration during placental development. Recent findings include HLA-G contributions from the father and the fetus itself. Much effort has been put into clarifying the role of HLA-G during pregnancy and pregnancy complications, such as preeclampsia, recurrent spontaneous abortions, and subfertility or infertility. This review aims to clarify the multifunctional role of HLA-G in pregnancy-related disorders by focusing on genetic variation, differences in mRNA stability betweenHLA-Galleles, differences in HLA-G isoform expression, and possible differences in functional activity. Furthermore, we highlight important observations regardingHLA-Ggenetics and expression in preeclampsia that future research should address.

1 April 2015 in Human Immunology
Verified
Journal Article
Closed access
LKLouise Klitkou
Louise Klitkou
MDMette Dahl
Mette Dahl
THThomas Vauvert Faurschou Hviid
Thomas Vauvert Faurschou Hviid
SDSnezana Djurisic
Snezana Djurisic
ZPZofia Maria Piosik
Zofia Maria Piosik
OCOle B. Christiansen
Ole B. Christiansen